Tefre K L, Ingerslev J, Sørensen B
University of Aarhus, Faculty of Health Sciences, Aarhus, Denmark.
Haemophilia. 2009 Jan;15(1):281-4. doi: 10.1111/j.1365-2516.2008.01902.x.
Bernard-Soulier syndrome (BSS) is a rare congenital bleeding disorder characterized by thrombocytopenia and giant platelets that display impaired or absent platelet agglutination with ristocetin. The disease is caused by mutations in genes controlling the expression of the platelet glycoprotein Ib-IX complex. The most severely affected patients suffer from profound muco-cutaneous bleeding tendency. Patients suffering from BSS may require platelet transfusion in prevention and management of severe bleeding. However, recent publications have suggested that recombinant factor VIIa (rFVIIa) infusion may support haemostasis in BSS. The present report describes two brothers who received treatment with rFVIIa together with tranexamic acid on a total of six occasions in management of haemostasis in minor surgery and for a serious spontaneous upper gastrointestinal tract bleed. Although platelet transfusion was omitted, haemostasis was regarded excellent in all of these treatment episodes.
伯纳德-索利尔综合征(BSS)是一种罕见的先天性出血性疾病,其特征为血小板减少和巨大血小板,这些血小板对瑞斯托霉素的凝集反应受损或缺乏。该疾病由控制血小板糖蛋白Ib-IX复合物表达的基因突变引起。受影响最严重的患者有严重的黏膜皮肤出血倾向。患有BSS的患者在预防和治疗严重出血时可能需要输注血小板。然而,最近的出版物表明,输注重组因子VIIa(rFVIIa)可能有助于BSS患者的止血。本报告描述了两名兄弟,他们在小型手术止血和严重自发性上消化道出血的治疗中,总共6次接受了rFVIIa联合氨甲环酸的治疗。尽管未输注血小板,但在所有这些治疗过程中止血效果均被认为极佳。